EHA 2023 CLLAN/AstraZeneca Patient Advocacy Exchange 10 June 2023

June 27, 2023

On Saturday 10 June, CLL Advocates Network and AstraZeneca hosted a “Patient Advocacy Exchange – Compromised: Uncovering the immune-related challenges facing people with CLL”.

This hybrid event brought together patient advocates, representatives of CLL concerned patient advocacy groups, members of clinical community and those with an interest in supporting patients with CLL.

90+ attendees from 60+ countries, including in person and virtual attendees, attended the meeting to:

  • Discuss insights and recommendations from “Compromised”: Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia” White Paper co-developed by CLL Advocates Network towards reshaping policy and practice.
  • Collaborate with patient advocates, patient advocacy organisations and the clinical communities to prioritise recommendations and associated call to actions
  • Explore the emotional and mental health impacts of CLL throughout the patient pathway
  • Consider possible advocacy initiatives to improve patient outcomes in CLL

Event agenda can be downloaded HERE.

This meeting provided a great opportunity to share information on how advocacy can support improvements in care and empower patients with CLL.

Huge thanks to our speakers Nick York, CLLAN Chair (UK); Professor Paul Moss, Professor of Haematology within the Institute of Immunology and Immunotherapy at the University of Birmingham (UK); Christina Karamanidou, CERTH (Greece); Natacha Bolaños, Head of Membership and Alliances, Lymphoma Coalition (Spain); Kathryn Huntley, General Manager, Leukemia Foundation (Australia); Zack Pemberton-Whitley, CEO Leukaemia Care (UK); and Dr Mervat Mattar, Haematologist, Cairo University (Egypt).

The event RECORDING will be available for viewing soon!

This event was funded by AstraZeneca.

Press Contacts

Nicole Schröter
CLLAN Project Manager
Get in Touch

Get in touch for information about the CLL Advocates Network and membership.

Read more